MAM
NVCT icon

Martingale Asset Management’s Nuvectis Pharma NVCT Stock Holding History

Martingale Asset Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331K Hold
18,024
– – 0.01% 739
2026
Q1 		$139K Buy
+18,024
New +$154K ﹤0.01% 785

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Martingale Asset Management's NVCT Position: Q2 2026 in Review

Martingale Asset Management held its Nuvectis Pharma (NVCT) position steady in Q2 2026 at 18,024 shares worth $331K. The position accounts for 0.01% of the portfolio, ranked #739.

Martingale Asset Management first reported a position in NVCT in Q1 2026 and has held it in 2 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Martingale Asset Management held 18,024 shares of Nuvectis Pharma worth $331K as of Q2 2026.
  • Martingale Asset Management left its Nuvectis Pharma share count unchanged in Q2 2026.
  • Nuvectis Pharma made up 0.01% of Martingale Asset Management's portfolio in Q2 2026, its #739 holding.
  • Martingale Asset Management first reported a position in Nuvectis Pharma in Q1 2026 and has held it in 2 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.